BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22154933)

  • 1. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
    Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
    J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel distribution following intraperitoneal administration in mice.
    Zahedi P; De Souza R; Piquette-Miller M; Allen C
    J Pharm Pharm Sci; 2011; 14(1):90-9. PubMed ID: 21501556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity.
    Zahedi P; De Souza R; Piquette-Miller M; Allen C
    Int J Pharm; 2009 Jul; 377(1-2):76-84. PubMed ID: 19442712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel.
    Yang Y; Wang J; Zhang X; Lu W; Zhang Q
    J Control Release; 2009 Apr; 135(2):175-82. PubMed ID: 19331864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.
    Zahedi P; De Souza R; Huynh L; Piquette-Miller M; Allen C
    Mol Pharm; 2011 Feb; 8(1):260-9. PubMed ID: 21166459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
    Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
    J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological characterization of human ovarian cancer cells in a rat model of intraperitoneal antineoplastic therapy.
    Flessner MF; Choi J; He Z; Credit K
    J Appl Physiol (1985); 2004 Oct; 97(4):1518-26. PubMed ID: 15180974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
    Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
    Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
    Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.
    Ozols RF; Locker GY; Doroshow JH; Grotzinger KR; Myers CE; Fisher RI; Young RC
    Cancer Treat Rep; 1979 Feb; 63(2):269-73. PubMed ID: 445504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.
    Esmaeili F; Dinarvand R; Ghahremani MH; Ostad SN; Esmaily H; Atyabi F
    Anticancer Drugs; 2010 Jan; 21(1):43-52. PubMed ID: 19809300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration.
    Lee E; Kim H; Lee IH; Jon S
    J Control Release; 2009 Dec; 140(2):79-85. PubMed ID: 19712714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
    Palma G; Conte C; Barbieri A; Bimonte S; Luciano A; Rea D; Ungaro F; Tirino P; Quaglia F; Arra C
    Int J Pharm; 2014 Oct; 473(1-2):55-63. PubMed ID: 24992317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
    Ye H; Tanenbaum LM; Na YJ; Mantzavinou A; Fulci G; Del Carmen MG; Birrer MJ; Cima MJ
    J Control Release; 2015 Dec; 220(Pt A):358-367. PubMed ID: 26548976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
    Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
    J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
    Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
    Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells.
    Kim CH; Kang TH; Kim BD; Lee TH; Yoon HY; Goo YT; Choi YS; Kang MJ; Choi YW
    Int J Pharm; 2020 Jun; 583():119393. PubMed ID: 32376445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.